{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:58:17Z","timestamp":1790481497805,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.survophthal.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:15:54Z","timestamp":1790205354000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of systemic fibrates on diabetic retinopathy prevention and progression: A comprehensive systematic review and meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-8335","authenticated-orcid":false,"given":"Luke","family":"Yaldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz","family":"Abdelaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Kiryakoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Sengillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Goldhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2026.09.006_bib1","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2337\/dc15-2171","article-title":"Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010","volume":"39","author":"Leasher","year":"2016","journal-title":"Diabetes care"},{"key":"10.1016\/j.survophthal.2026.09.006_bib2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/dc09-0615","article-title":"Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis","volume":"32","author":"Wong","year":"2009","journal-title":"Diabetes care"},{"key":"10.1016\/j.survophthal.2026.09.006_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.visres.2017.04.010","article-title":"The role of dyslipidemia in diabetic retinopathy","volume":"139","author":"Hammer","year":"2017","journal-title":"Vision Res"},{"key":"10.1016\/j.survophthal.2026.09.006_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1089\/jop.2020.0068","article-title":"Effects of modified low-density lipoproteins and fenofibrate on an outer blood-retina barrier model: Implications for diabetic retinopathy","volume":"36","author":"Fu","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2026.09.006_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11892-016-0786-7","article-title":"Fenofibrate and diabetic retinopathy","volume":"16","author":"Knickelbein","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.survophthal.2026.09.006_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.09.006_bib7","first-page":"554","article-title":"Double-blind trial of Atromid-S in exudative diabetic retinopathy","volume":"94","author":"Cullen","year":"1974","journal-title":"Trans Ophthalmol Soc U Kingd"},{"key":"10.1016\/j.survophthal.2026.09.006_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0028-1109516","article-title":"Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy","volume":"226","author":"Emmerich","year":"2009","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.survophthal.2026.09.006_bib9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2026.09.006_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13340-018-0357-z","article-title":"Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4)","volume":"10","author":"Kawasaki","year":"2019","journal-title":"Diabetol Int"},{"key":"10.1016\/j.survophthal.2026.09.006_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2024.100771","article-title":"Association between pentoxifylline use and diabetic retinopathy in patients with type 2 diabetes mellitus and chronic kidney disease: A multi-institutional cohort study","volume":"48","author":"Lin","year":"2025","journal-title":"Biomed J"},{"key":"10.1016\/j.survophthal.2026.09.006_bib12","article-title":"Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan","volume":"56","author":"Lin","year":"2020","journal-title":"Med (Kaunas)"},{"key":"10.1016\/j.survophthal.2026.09.006_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcjo.2021.01.002","article-title":"Low prevalence of fibrate use in adults with type 1 and type 2 diabetes and established diabetic retinopathy","volume":"56","author":"Morein","year":"2021","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.oret.2024.12.006","article-title":"Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus","volume":"9","author":"Muayad","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"92","key":"10.1016\/j.survophthal.2026.09.006_bib15","article-title":"Statins and\/or fibrates for diabetic retinopathy: a systematic review and meta-analysis","volume":"11","author":"Mozetic","year":"2019","journal-title":"Diabetol & Metab Syndr"},{"key":"10.1016\/j.survophthal.2026.09.006_bib16","article-title":"Relationship between dyslipidemia and diabetic retinopathy: A systematic review and meta-analysis","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.survophthal.2026.09.006_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202347","article-title":"Development of diabetic retinopathy after cataract surgery","volume":"13","author":"Jeng","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2026.09.006_bib18","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1111\/dom.13372","article-title":"Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: a real-world observational analysis of a health claims database","volume":"20","author":"Kawasaki","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.survophthal.2026.09.006_bib19","article-title":"A medication-wide association study to identify medications associated with incident clinically significant diabetic retinopathy","volume":"15","author":"Xiong","year":"2023","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"bmj 372"},{"key":"10.1016\/j.survophthal.2026.09.006_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.survophthal.2026.09.006_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12886-022-02323-z","article-title":"Effect of anticoagulant\/antiplatelet therapy on the development and progression of diabetic retinopathy","volume":"22","author":"Jeng","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161897","article-title":"Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression","volume":"11","author":"Jeng","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2026.09.006_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1248\/yakushi.20-00259","article-title":"Effects of fibrates on risk of development of diabetic retinopathy in japanese working age patients with Type 2 diabetes and dyslipidemia: a retrospective cohort study","volume":"141","author":"Akimoto","year":"2021","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.survophthal.2026.09.006_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.survophthal.2026.09.006_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1081\/SAC-200040691","article-title":"Small sample confidence intervals for the odds ratio","volume":"33","author":"Lawson","year":"2004","journal-title":"Commun Stat-Simul Comput"},{"key":"10.1016\/j.survophthal.2026.09.006_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001923","article-title":"Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes","volume":"9","author":"Wakasugi","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.survophthal.2026.09.006_bib28","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00125-011-2198-1","article-title":"Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients","volume":"54","author":"Hammes","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.survophthal.2026.09.006_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaophthalmol.2022.0633","article-title":"Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy","volume":"140","author":"Meer","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application","volume":"126","author":"Minozzi","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.13105\/wjma.v5.i4.80","article-title":"Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale","volume":"5","author":"Luchini","year":"2017","journal-title":"World J Meta-Anal"},{"key":"10.1016\/j.survophthal.2026.09.006_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14407","article-title":"The association between carotid disease, arterial stiffness and diabetic retinopathy in type 2 diabetes: the Fremantle Diabetes Study Phase II","volume":"38","author":"Drinkwater","year":"2021","journal-title":"Diabet Med"},{"key":"10.1016\/j.survophthal.2026.09.006_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000304","article-title":"Prevalence and associated risk factors of diabetic retinopathy and macular oedema in patients recently diagnosed with type 2 diabetes","volume":"5","author":"Graue-Hernandez","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib34","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/bjo-2023-324930","article-title":"Evaluation of systemic medications associated with diabetic retinopathy: a nested case-control study from the UK Biobank","volume":"108","author":"Jin","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.12816\/0004460","article-title":"Risk Factors for Diabetic Retinopathy in Patients Attending Primary Care Settings","volume":"36","author":"Nasser","year":"2014","journal-title":"Bahrain Med Bull"},{"key":"10.1016\/j.survophthal.2026.09.006_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12886-018-0769-3","article-title":"The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4093\/dmj.2013.37.4.262","article-title":"Diabetic retinopathy and endothelial dysfunction in patients with type 2 diabetes mellitus","volume":"37","author":"Yun","year":"2013","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.survophthal.2026.09.006_bib38","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41433-024-03022-3","article-title":"Associations between lipid abnormalities and diabetic retinopathy across a large United States national database","volume":"38","author":"Jeong","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2026.09.006_bib39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4093\/dmj.2016.40.6.473","article-title":"Risk Factors for the Development and Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Advanced Diabetic Retinopathy","volume":"40","author":"Yun","year":"2016","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.survophthal.2026.09.006_bib40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","article-title":"Use of the GRADE approach in systematic reviews and guidelines","volume":"123","author":"Granholm","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.survophthal.2026.09.006_bib41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2026.09.006_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101428","article-title":"Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study","volume":"49","author":"Kim","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.survophthal.2026.09.006_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.diabres.2014.07.027","article-title":"Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan--a 3-year prospective study","volume":"106","author":"Lee","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.survophthal.2026.09.006_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/09286586.2014.949783","article-title":"Effects of fenofibric acid on diabetic macular edema: the MacuFen study","volume":"21","author":"Massin","year":"2014","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004025","article-title":"Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study","volume":"3","author":"Morgan","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.survophthal.2026.09.006_bib46","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of Fenofibrate on Progression of Diabetic Retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.survophthal.2026.09.006_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206674","article-title":"Effect of Lipids on Diabetic Retinopathy in a Large Cohort of Diabetic Patients after 10 Years of Follow-Up","volume":"12","author":"Romero-Aroca","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2026.09.006_bib48","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.12953","article-title":"Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus","volume":"10","author":"Song","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.survophthal.2026.09.006_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112306","article-title":"Association between long-term serum uric acid variability and diabetic retinopathy: A prospective study in patients with Type 1 and Type 2 diabetes","volume":"226","author":"Zhu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.survophthal.2026.09.006_bib50","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.3892\/mmr.2015.4164","article-title":"Feno\ufb01brate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway","volume":"12","author":"Zhao","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.survophthal.2026.09.006_bib51","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1167\/iovs.18-24155","article-title":"Fenofibrate exerts protective effects in diabetic retinopathy via inhibition of the ANGPTL3 pathway","volume":"59","author":"Wang","year":"2018","journal-title":"Invest Ophthalmol & Vis Sci"},{"key":"10.1016\/j.survophthal.2026.09.006_bib52","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.8b01319","article-title":"Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration","volume":"16","author":"Qiu","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.survophthal.2026.09.006_bib53","article-title":"Fenofibrate for diabetic retinopathy","author":"Kataoka","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.survophthal.2026.09.006_bib54","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.2337\/db13-0800","article-title":"An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes","volume":"62","author":"Noonan","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.survophthal.2026.09.006_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/aos.14377","article-title":"Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review","volume":"98","author":"Elkjaer","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.09.006_bib56","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2026.09.006_bib57","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.survophthal.2026.09.006_bib58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.2337\/dc22-1711","article-title":"Retinopathy During the First 5 Years of Type 1 Diabetes and Subsequent Risk of Advanced Retinopathy","volume":"46","author":"Malone","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.survophthal.2026.09.006_bib59","first-page":"367","article-title":"The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review","volume":"44","author":"Sharma","year":"2015","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.survophthal.2026.09.006_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2012.03.013","article-title":"Fenofibrate\u2013a potential systemic treatment for diabetic retinopathy?","volume":"154","author":"Wong","year":"2012","journal-title":"Am J Ophthalmol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:22:45Z","timestamp":1790479365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"alternative-id":["S0039625726001402"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.09.006","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of systemic fibrates on diabetic retinopathy prevention and progression: A comprehensive systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}